Key facts
- It has raised $70.4M; the latest was Later Stage VC in Mar 2026.
- Notable investors include OrbiMed, Vivo Capital, Hechuang Era Private Equity Fund Management, Irobust Capital, LAV (Lilly Asia Fund).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Createrna
- ·The full record, as it builds
Funding rounds
No funding rounds for Createrna are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Createrna
Manufacturer of an innovative drug, a research and development company, intended to treat clinically significant diseases. The company is committed to building new drug development pipelines and platforms for the treatment of diseases such as refractory chronic cough, idiopathic pulmonary fibrosis, kidney diseases, pain, cardiovascular diseases, and autoimmune diseases, enabling clients to assess a drug's clinical, economic, and societal merit within the broader treatment landscape.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2013
- Employees
- 290
- Website
- createrna.com/
- Ownership
- Privately Held (backing)
Createrna doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Createrna shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Createrna in its N-PORT filings yet. We sweep new filings monthly.